Drug Profile
Human papillomavirus vaccine TA-HPV - Xenova
Alternative Names: TA-HPVLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator
- Developer Xenova Group
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Vulvar intraepithelial neoplasia
Most Recent Events
- 29 Jul 2004 Suspended - Phase-II for Anal intraepithelial neoplasia in United Kingdom (Intradermal)
- 29 Jul 2004 Suspended - Phase-II for Cervical cancer in European Union (Intradermal)
- 29 Jul 2004 Suspended - Phase-II for Cervical cancer in United Kingdom (Intradermal)